Gaetane Nocturne , Marjolaine Gosset , Antoine Rousseau
{"title":"Traitements présents et futurs du syndrome sec au cours du syndrome de Gougerot-Sjögren primitif","authors":"Gaetane Nocturne , Marjolaine Gosset , Antoine Rousseau","doi":"10.1016/j.monrhu.2021.04.002","DOIUrl":null,"url":null,"abstract":"<div><p>Primary Sjögren's syndrome (pSS) is characterized by the association of a symptomatic triad (dryness, pain and fatigue) with various systemic manifestations. While systemic involvement affects about 30 % of patients, sicca, mainly ocular and oral, is present in almost all patients. This symptom causes high burden of the disease and a marked deterioration in quality of life. It should not be neglected in the management of pSS patients. The purpose of this update is to provide a review of the mechanisms that cause dry syndrome in pSS, to outline the potential consequences of this symptom, and to give practical tools to guide the management of our pSS patients. Finally, this article reviews the impact of targeted therapies in development in pSS on dryness.</p></div>","PeriodicalId":101125,"journal":{"name":"Revue du Rhumatisme Monographies","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.monrhu.2021.04.002","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue du Rhumatisme Monographies","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1878622721000643","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Primary Sjögren's syndrome (pSS) is characterized by the association of a symptomatic triad (dryness, pain and fatigue) with various systemic manifestations. While systemic involvement affects about 30 % of patients, sicca, mainly ocular and oral, is present in almost all patients. This symptom causes high burden of the disease and a marked deterioration in quality of life. It should not be neglected in the management of pSS patients. The purpose of this update is to provide a review of the mechanisms that cause dry syndrome in pSS, to outline the potential consequences of this symptom, and to give practical tools to guide the management of our pSS patients. Finally, this article reviews the impact of targeted therapies in development in pSS on dryness.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
